Christopher Marai


Oppenheimer Pounds the Table on Sarepta Therapeutics Inc (SRPT)

Oppenheimer analyst Christopher Marai was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating an Outperform rating and price target of $60, which …

Here’s Why Oppenheimer Raised Price Target for Sarepta Therapeutics Inc (SRPT)

In a research report published Wednesday, Oppenheimer’s healthcare analyst Christopher Marai reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), while raising the price target …

Oppenheimer Shines Light on BioMarin Pharmaceutical Inc. (BMRN) Following FDA Advisory Meeting for Kyndrisa

Oppenheimer analyst Christopher Marai came out today with a few insights on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), after attending the FDA advisory meeting for Kyndrisa, the company’s treatment for Duchenne …

Oppenheimer Reiterates Outperform on Sarepta Therapeutics Inc Ahead of WMS Conference

In a research report released Monday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ :SRPT), with a price …

Oppenheimer Maintains Outperform on CytRx Corporation Following 2Q:15 Update

Oppenheimer’s healthcare analyst Christopher Marai came out with a research report on CytRx Corporation (NASDAQ:CYTR), reiterating an Outperform rating and a $10 price …

Oppenheimer Maintains Outperform on Celldex Therapeutics, Inc. Following DSMN Recommendation to Continue P3 Trial of RINTEGA + SOC temzolomide

Oppenheimer analyst Christopher Marai offered some of his opinions on Celldex Therapeutics, Inc. (NASDAQ:CLDX) following a DSMB recommendation to continue the ongoing P3 trial (ACT-IV) …

Oppenheimer Maintains Outperform on Sarepta Therapeutics Inc Following Completed Rolling NDA for Eteplirsen

Oppenheimer analyst Christopher Marai came out with a research report on Sarepta Therapeutics Inc (NASDAQ:SRPT) after the company completed its rolling NDA for eteplirsen, a trial …

Oppenheimer Maintains Outperform on Uniqure NV; Sees 49% Upside For The Stock

In a research report released Sunday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Uniqure NV (NASDAQ:QURE) with a price target of $47, …

Oppenheimer Remains Optimistic on Incyte Corporation Following Data Presented at EULAR

Oppenheimer analyst Christopher Marai came out with some insights on Incyte Corporation (NASDAQ:INCY) after detailed data from the baricitinib BUILD and BEACON P3 studies was …

Oppenheimer Initiates Coverage on Agenus Inc Following Collaborations With Merck & Co., Inc. and Incyte Corporation

Oppenheimer analyst Christopher Marai initiated coverage on Agenus Inc (NASDAQ:AGEN) after the company began collaborations with Merck and Incyte for the discovery and development of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts